Tirzepatide
Dual GIP/GLP-1 Receptor Agonist
Also known as: Mounjaro (type 2 diabetes), Zepbound (weight management)
Last updated May 8, 2026
What is Tirzepatide?
You’ve done the research on Ozempic and Wegovy. Now you keep seeing another name: Mounjaro, Zepbound, tirzepatide. The claims sound almost too good — more weight loss than semaglutide, dual-action mechanism, head-to-head trial data to back it up. But every article you find is from a telehealth company selling prescriptions or a compounder hawking knockoffs in legally contested territory. You want to know what the trials actually showed, the access landscape now and whether the compounding option that got you here is even legal anymore. Here’s the independent assessment.
Tirzepatide is the first dual-action incretin mimetic — a synthetic molecule that activates two gut hormone receptors simultaneously. It targets both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Your body naturally produces both GIP and GLP-1 after eating — together they regulate appetite, blood sugar and fat metabolism. Tirzepatide mimics both hormones with a single weekly injection.
This dual mechanism is why tirzepatide produces greater weight loss than semaglutide, which only targets GLP-1. The GIP component adds improved fat metabolism, enhanced insulin sensitivity through a separate pathway and potentially better tolerability at higher effective doses. Manufactured by Eli Lilly as Mounjaro (diabetes) and Zepbound (weight management). Both are exactly the same medication — the difference is the FDA-approved indication, which affects insurance coverage.
What Does the Research Actually Show?
SURMOUNT-1 trial (2,539 participants without diabetes) showed 15.0% weight loss at 5mg, 19.5% at 10mg and 20.9% at 15mg over 72 weeks vs 3.1% placebo. Over a third on the highest dose lost 25%+ — previously achievable only with bariatric surgery.
SURMOUNT-5 trial (751 participants, NEJM May 2025) directly compared the two. Tirzepatide achieved 20.2% weight loss vs 13.7% for semaglutide at 72 weeks. Statistically superior on both weight loss and waist circumference.
SURPASS trial program with significant HbA1c reductions. SURPASS-2 showed tirzepatide beat semaglutide 1mg at all three dose levels. Many participants reached A1c below 5.7% — the non-diabetic range. SURMOUNT-1 data also showed 94% reduction in risk of progressing from prediabetes to type 2 diabetes.
SURMOUNT-OSA trial led to FDA approval of Zepbound for moderate-to-severe OSA in adults with obesity — the first drug approved for this condition based on weight reduction.
Active investigation in MASH/NASH, heart failure with preserved ejection fraction and chronic kidney disease.
How Is Tirzepatide Administered?
| Route | Weekly subcutaneous injection (abdomen, thigh or upper arm) |
| Frequency | Once weekly via pre-filled pen (KwikPen) or single-dose vial |
| Dose escalation | Starts at 2.5mg weekly, escalates by 2.5mg every 4 weeks as tolerated to maintenance (5mg, 10mg or 15mg, provider-determined) |
| Access | Prescribed by licensed providers; FDA-approved (Mounjaro, Zepbound) at retail pharmacies |
For a guide to injection supplies and self-administration basics, see our Injectable Peptide Supplies Guide →
What Are the Side Effects and Risks?
- GI effects (nausea, diarrhea, vomiting, decreased appetite, constipation, dyspepsia) — most common, usually during dose escalation. Slow escalation and smaller meals help.
- Muscle loss — weight loss includes lean mass reduction, underreported across the GLP-1 class. Resistance training and protein intake (1g/kg/day minimum) are important.
- Pancreatitis — rare but reported.
- Thyroid concerns — boxed warning, contraindicated with medullary thyroid carcinoma history or MEN 2.
- Gallbladder issues — increased gallstone and cholecystitis risk from rapid weight loss.
- Injection site reactions — generally mild, rotate sites weekly.
- Hypoglycemia — low risk alone, increases with insulin or sulfonylureas.
- Weight regain — SURMOUNT-4 showed significant regain after discontinuation. Cleveland Clinic real-world data (March 2026, ~8,000 patients) suggests better outcomes when patients restart or switch, but regain after stopping is consistent across all GLP-1 class drugs.
See our independent week-by-week guide to what to expect on tirzepatide, including side effects the clinical trials missed Read the tirzepatide timeline →
Who Should NOT Use Tirzepatide?
If you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): This is a boxed warning — the FDA’s most serious category. Animal studies showed thyroid C-cell tumors. This is not a theoretical hedge. It is a hard contraindication.
If you have a history of pancreatitis: Rare cases of acute pancreatitis have been reported. If you’ve had pancreatitis before, the risk-benefit calculation changes significantly. Your provider needs to weigh this explicitly.
If you have a history of gallbladder disease: Tirzepatide increases the risk of gallstones and cholecystitis, driven by rapid weight loss. If you’ve had gallbladder issues — or have already had your gallbladder removed — discuss this with your provider before starting.
If you are pregnant, planning to become pregnant or breastfeeding: Tirzepatide is contraindicated in pregnancy. The FDA recommends discontinuing at least 2 months before a planned pregnancy due to the drug’s long half-life. There is no safety data in breastfeeding.
If you have a history of eating disorders: Tirzepatide dramatically reduces appetite and alters your relationship with food. For someone with a history of anorexia or restrictive eating patterns, this appetite suppression can reinforce disordered behaviors. A provider who understands both metabolic health and eating disorder history should be involved — not just someone who will write the prescription.
If you have diabetic retinopathy: GLP-1 class drugs have been associated with increased retinopathy complications in patients with type 2 diabetes. If you have existing diabetic retinopathy, your ophthalmologist and prescriber both need to be aware.
If you have severe gastrointestinal disease: Gastroparesis or other conditions involving significantly delayed gastric emptying may be worsened. Tirzepatide slows stomach emptying as part of its mechanism — adding this on top of an existing motility disorder requires careful clinical judgment.
If you are using compounded tirzepatide from any source: As of April 2026, there is no legitimate large-scale compounded tirzepatide available. The FDA removed tirzepatide from the drug shortage list in October 2024. Enforcement discretion for 503A pharmacies ended February 2025; 503B ended March 2025. Courts upheld the FDA’s position May 2025. Some 503A pharmacies may still compound under narrow individual-patient exceptions with documented clinical justification, but bulk compounded tirzepatide is no longer legally available. If your provider is offering “compounded tirzepatide” without clear documentation of why the commercial version doesn’t meet your clinical needs, that’s a red flag.
If your BMI doesn’t meet prescribing criteria and you’re seeking it for cosmetic weight loss: Zepbound is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity. Using it below these thresholds means you’re outside the studied population, insurance is unlikely to cover off-label use and the risk-benefit ratio hasn’t been established for your situation.
Before You Start: Get Baseline Labs
Standard baseline workup for any GLP-1 / GIP receptor agonist applies to tirzepatide. Tirzepatide’s dual mechanism warrants slightly broader baseline labs than semaglutide alone.
Baseline workup before starting:
- HbA1c, fasting glucose — primary efficacy markers
- Lipid panel — tirzepatide produces stronger lipid improvements than semaglutide in trials; baseline gives reference
- Comprehensive metabolic panel (CMP) — kidney function, liver enzymes, electrolytes
- TSH, free T4 — thyroid screening; the FDA boxed warning on medullary thyroid carcinoma makes this particularly important
- Lipase — pancreatitis baseline reference
If your provider isn’t recommending baseline labs, that’s worth questioning — this is standard of care for any FDA-approved tirzepatide prescribing.
For ongoing monitoring once you’re on tirzepatide, see our What to Expect on Tirzepatide guide.
Order at-home labs from Everlywell →Lab recommendations are the same regardless of which service you use.
- 1Am I a good candidate for tirzepatide based on my BMI, health history and goals?
- 2Why tirzepatide over semaglutide for my situation?
- 3What’s your plan for managing GI side effects during dose escalation?
- 4How will we protect against muscle loss?
- 5What does long-term maintenance look like? What happens if I stop the medication?
- 6What is the prescription pathway, and what manufacturer access programs exist for the FDA-approved formulations?
- 7Are you prescribing FDA-approved tirzepatide (Zepbound/Mounjaro), or a compounded version?
- 8How will you monitor my progress — frequency and metrics beyond weight?
Already on tirzepatide? See our week-by-week guide Open the tirzepatide timeline →
Is Tirzepatide Legal in 2026?
Tirzepatide is FDA-approved and available through standard prescriptions at licensed pharmacies. As of April 2026, broad compounding is effectively prohibited. The FDA removed tirzepatide from its drug shortage list in October 2024 and enforcement discretion has ended — 503A in February 2025, 503B in March 2025. In May 2025, the U.S. District Court upheld the FDA's decision. Eli Lilly is aggressively enforcing its patents and trademarks against compounders and telehealth companies. Some companies continue offering “personalized” tirzepatide formulations arguing they're not “essentially a copy” — the FDA has rejected this reasoning and the legal landscape mirrors semaglutide's enforcement trajectory.
On April 30, 2026, the FDA proposed excluding tirzepatide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound it from bulk drug substances. The agency clarified that supply issues, convenience and cost aren't part of the clinical-need analysis. If finalized, this would close the remaining 503B pathway for compounded tirzepatide entirely. Public comment runs through June 29, 2026.
A Medicare GLP-1 Bridge program has been announced for mid-2026. No generic versions of tirzepatide are expected until the early 2030s.
How Do I Get Tirzepatide Through a Legitimate Provider?
These providers meet our evaluation criteria: verified medical license, labs required before prescribing, and medications sourced from licensed U.S. pharmacies.
Peter MD
Hormone optimization, peptides, and longevity. Labs required before prescribing.
Not available in ID, AL. Lab work not available in NY, NJ, RI.
Book a ConsultationEnhance MD
Physician-led metabolic wellness. Comprehensive labs and ongoing provider monitoring included.
Not available in AL, AR, GA, HI, LA, MS, MO, ND, SC, TN, WV.
Book a ConsultationWe continuously evaluate providers. New additions will appear here as they’re verified.
These are affiliate links. We may earn a commission if you book through them. This never influences our evidence ratings or recommendations.